[Edgewater Co., Ltd.] A pilot study of “observational research” on human immunity and genes will be conducted by the National Research and Development Corporation.
Conducted joint research with RIKEN. Recruiting participation from pharmaceutical companies to measure immune status before and after drug administration
*Edgewater Co., Ltd.*
Press release: September 11, 2024
**
A pilot study of “observational research” on human immunity and genes will be conducted by the National Research and Development
Corporation.
Conducted joint research with RIKEN. Recruiting participation from pharmaceutical companies to measure immune status before and after drug administration
*Edgewater has entered into a basic agreement with RIKEN to conduct joint research to develop a “disease risk prediction system” and “diagnosis support system” using AI analysis technology by collecting large-scale immune and genetic data of patients with various diseases. Signing *
*
The significance of pharmaceutical companies participating in this pilot study is that by measuring the patient’s immune status before and after the pharmaceutical company’s specific drug is administered to the patient, we will be able to determine how the drug affects the patient’s immune status. It’s something you can understand. *
* Also, if this data is collected on a large scale, AI x big data analysis will lead to research into disease prevention and causes. * * In addition, in this “observational research” in which precious patient blood samples are obtained, it is also possible to add “various tests that can be measured using blood” as an option if desired by the pharmaceutical company. *
* Furthermore, as a result of this “observational study”, it is assumed that this will have the effect of supporting the sales of pharmaceutical companies, so we plan to verify this as well. *
Therefore, Edgewater is inviting pharmaceutical companies to participate in this pilot study.
We hope that many pharmaceutical companies will consider participating.
* -Pilot study implementation overview-*
1. Purpose: 1. Perform the following tests before and after
administering drugs from the target pharmaceutical company.
・Genetic test 1 time
・Immunology test 2 times
2. Analyze the above test results using AI and conduct PoC for “disease risk prediction”
3. Measure the effectiveness of sales support through observational research.
2. Implementation period: December 2024 to November 2025 (planned)
3. Results report: Feedback of the above genetic and immune data and AI analysis results to participating pharmaceutical companies
4. Cooperation: National Research and Development Agency RIKEN Center for Integrative Medical Sciences Autoimmune Disease Team
GeneQuest Co., Ltd.
* -contact address-*
If you are a pharmaceutical company interested in this pilot study, please contact us at the email address below.
We will explain the details online or in person. Please feel free to join us. ＊ info@edgewater-hig.com
[About Edgewater Co., Ltd.]
In 1999, while working at MSD, founder Fukuzawa was seconded to Medco (currently Express Scripts), a wholly owned subsidiary of MSD in the U.S., and his use of medical data such as receipts greatly contributed to the development of medical care. Learn what to do. Based on this experience, in 2023 we obtained patents for “disease risk prediction” and “diagnosis support system” using “immunity” as a parameter.
In 2023, Dr. Yasushi Okumura, an international authority on
immunology, Specially Appointed Professor of Immunology at Juntendo University School of Medicine, and Director of the Atopic Disease Research Center, will be appointed as our scientific advisor.
Company name: Edgewater Co., Ltd.
Location: 5-3-10 Seijo, Setagaya-ku, Tokyo
Established: January 15, 2015
Capital: 26.47 million yen (including capital reserves)
Representative: Representative Director Masahiko Fukuzawa
Business content: Immunology/gene AI big data bank business
Member organization: Juntendo University Graduate School of Medicine, member of AI Incubation Farm Partners
URL: https://www.edgewatermf.com/
[Representative career]
1978: Graduated from Meiji University Faculty of Engineering and joined MSD Corporation (successful positions in sales, human resources, corporate planning, corporate advertising, sales
management, etc.)
1999: Seconded to Medco (then a subsidiary of MSD in the US, now Express Scripts)
2002: MSD Corporation New Business Manager
2004: Established Global Health Care Co., Ltd. and became president and representative director.
2007: Established SBI Wellness Bank Co., Ltd. Appointed representative director and COO
2013: Appointed as executive officer of Kenko Com Co., Ltd.
2015: Founded Edgewater Co., Ltd. Appointed CEO
2017: Founded Immunity Research Co., Ltd. Appointed representative director